TherapeuticsMD, Inc.
TXMD
$1.46
-$0.06-3.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.19% | 156.93% | 53.54% | 35.25% | -97.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.19% | 156.93% | 53.54% | 35.25% | -97.70% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 75.19% | 156.93% | 53.54% | 35.25% | -97.70% |
| SG&A Expenses | -22.88% | -20.92% | -37.19% | -46.71% | -69.94% |
| Depreciation & Amortization | -63.00% | -64.17% | -54.18% | -44.79% | 76.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.45% | -27.89% | -39.32% | -46.53% | -65.22% |
| Operating Income | 64.31% | 60.16% | 55.23% | 59.03% | -109.39% |
| Income Before Tax | 100.25% | 87.55% | 64.72% | 69.74% | -109.48% |
| Income Tax Expenses | -46.51% | -46.51% | -46.51% | 27.91% | -- |
| Earnings from Continuing Operations | 101.84% | 88.75% | 65.49% | 69.97% | -109.38% |
| Earnings from Discontinued Operations | -64.82% | 106.79% | 103.22% | 105.08% | -97.50% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 109.11% | 92.46% | 71.66% | 78.78% | -104.85% |
| EBIT | 64.31% | 60.16% | 55.23% | 59.03% | -109.39% |
| EBITDA | 68.71% | 63.09% | 58.75% | 63.10% | -108.20% |
| EPS Basic | 108.97% | 92.81% | 73.85% | 81.12% | -104.00% |
| Normalized Basic EPS | 60.41% | 53.57% | 68.87% | 73.14% | -104.44% |
| EPS Diluted | 106.09% | 91.82% | 73.30% | 81.25% | -104.73% |
| Normalized Diluted EPS | 60.41% | 53.57% | 68.87% | 73.14% | -105.16% |
| Average Basic Shares Outstanding | 1.30% | 3.09% | 6.10% | 10.58% | 13.65% |
| Average Diluted Shares Outstanding | 1.30% | 3.09% | 6.10% | 10.58% | 9.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |